R8-modified MITO-Porter (no RNA aptamer)
Sequence: RRRRRRRR
RNA aptamer (2′-O-methyl, cholesterol-conjugated) [ligand; not therapeutic payload]
| Experiment Id | EXP001951 |
|---|---|
| Paper | A Dual-Ligand Liposomal System Composed of a Cell-Penetrating Peptide and a Mitochondrial RNA Aptame |
| Peptide | R8-modified MITO-Porter (no RNA aptamer) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | no |
| Endosomal Escape Evidence | |
| Peptide Concentration | R8 at 10 mol% of total lipids (surface attachment after liposome formation). |
| Rna Concentration | Chol-RNA aptamer at 2.5 mol% of total lipids (dual-ligand variants); NBD-DOPE used as tracer. |
| Mixing Ratio | DOPE/sphingomyelin/NBD-DOPE (9:2:0.1) with ± 2.5 mol% Chol-aptamer; then add stearylated R8 to 10 mol% total lipid. |
| Formulation Format | Liposome (MITO-Porter) with peptide + RNA aptamer dual-ligand surface |
| Formulation Components | DOPE/sphingomyelin/NBD-DOPE (9:2:0.1 molar). R8 device ± Chol-RNA aptamer (RP/MRP/D-arm). |
| Size Nm | 134.00 |
| Zeta Mv | 22.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HeLa (human cervix carcinoma) cells |
| Animal Model | |
| Administration Route | |
| Output Type | Uptake + mitochondrial targeting (flow cytometry MFI; confocal colocalization with mitochondria) |
| Output Value | Dual-ligand (aptamer/R8) increases cellular uptake vs R8-only and improves mitochondrial targeting/occupancy; RP/R8 at 2.5 mol% reported as optimal among tested aptamers. |
| Output Units | |
| Output Notes | Readouts: flow cytometry of NBD-labeled liposomes after 3 h; CLSM colocalization with Mitofluor-stained mitochondria; mechanistic inhibitor studies (sucrose/amiloride; FCCP/oligomycin) probe uptake/targeting pathways. |
| Toxicity Notes | |
| Curation Notes |